Nerthuz/iStock through Getty Pictures
- Evoke Pharma (NASDAQ:EVOK) mentioned on Tuesday that it has obtained roughly $3M in gross proceeds from the modification and train of present warrants.
- The gross proceeds can be used to assist working capital and common company functions, together with advancing the industrial efforts for its nasal spray, GIMOTI.
- As a part of the transaction, Nantahala Capital Administration, an present investor and warrant holder, has been granted the precise to appoint two members to the corporate’s board.
